Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.

J Clin Hypertens (Greenwich) · 2020 · PMC7590106 · PMID 32810338

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendP = .059so close (0.05 < p ≤ 0.1)

33 Post hoc analysis of data from the EMPA‐REG BP trial showed a trend toward a reduction in the ambulatory arterial stiffness index ( P = .059) in patients with type 2 diabetes mellitus treated with empagliflozin for 24 weeks. 34 Looking specifically at CAVI, this was significantly reduced 6 months after switching from a dipeptidyl peptidase‐4 (DPP‐4) inhibitor t

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.